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Abstract
Lipin-1 is a protein that has dual functions as a phosphatidic acid phosphohydrolase (PAP) and a nuclear transcriptional
coactivator. It remains unknown how the nuclear localization and coactivator functions of lipin-1 are regulated. Here, we
show that lipin-1 (including both the alpha and beta isoforms) is modified by sumoylation at two consensus sumoylation
sites. We are unable to detect sumoylation of the related proteins lipin-2 and lipin-3. Lipin-1 is sumoylated at relatively high
levels in brain, where lipin-1a is the predominant form. In cultured embryonic cortical neurons and SH-SY5Y neuronal cells,
ectopically expressed lipin-1a is localized in both the nucleus and the cytoplasm, and the nuclear localization is abrogated
by mutating the consensus sumyolation motifs. The sumoylation site mutant of lipin-1a loses the capacity to coactivate the
transcriptional (co-) activators PGC-1a and MEF2, consistent with its nuclear exclusion. Thus, these results show that
sumoylation facilitates the nuclear localization and transcriptional coactivator behavior of lipin-1a that we observe in
cultured neuronal cells, and suggest that lipin-1a may act as a sumoylation-regulated transcriptional coactivator in brain.
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Introduction
Covalent attachment of the small ubiquitin-like modifiers
(SUMOs) to lysine residues in target proteins, or sumoylation, is
an important regulator of protein functions [1–4]. Sumoylation of
target proteins is a multi-step process involving the E1-activating
complex Aos1/Uba2 and the E2-conjugating enzyme Ubc9 in
mammalian cells. These two suffice to drive SUMO conjugation in
vitro. In vivo, sumoylation typically involves E3 factors, which
enhance the specificity and rate of modification. SUMO
modification usually is reversible, and multiple SUMO-specific
proteases that remove the modification have been identified [5,6].
The substrate lysines for sumoylation are typically found within
the consensus sequence WKXE (W represents hydrophobic amino
acids; K, lysine; X, any amino acid; E, glutamate). Cells express
three major SUMO paralogs, SUMO-1, SUMO-2, and SUMO-3,
with SUMO-2 and 3 being much more similar to each other than
to SUMO-1 [2]. Many nuclear proteins are sumoylated and this
has been linked to nuclear localization, transcriptional activation
or repression, and other processes [7-9]. Proteins whose nuclear
localization is facilitated by sumoylation include CtBP1 [10],
CREB [11], Mdm2 [12] and KLF5 [13].
The protein encoded by the LPIN1 gene (lipin-1) has been
implicated in the regulation ofcellularlipid metabolismin a varietyof
tissues including adipose tissue [14], liver [15], muscle [16], and
myelinated motor neurons [17]. LPIN1, was discovered using a
positional cloning approach to identify the genetic mutation
responsible for the fatty liver dystrophic (fld) mouse phenotype [18].
Fld mice exhibit life-long deficiency in adipocyte differentiation,
peripheral neuropathy, circulating hyperlipidemia, and neonatal
hepatic steatosis [19–21]. Conversely, transgenic lipin-1 overexpres-
sion in skeletal muscle or white adipose tissue of mouse exacerbates
high-fat diet-induced obesity due to effects on adipocytes [16]. In
higher eukaryotes, genes encoding three lipin family members (lipin-
1, lipin-2, and lipin-3) have been identified [18]. In addition, two
lipin-1 protein isoforms (lipin-1a and lipin-1b) are generated by
alternative mRNA splicing [14,22]. In humans, mutations in LPIN1
are associated with metabolic syndrome and type-2 diabetes [19,23].
Both mammalian lipin-1 and its budding yeast homolog (PAH1 or
SMP2) were revealed to have enzymatic activity as a phosphatidic
acid phosphohydrolase (PAP) [24]. PAP proteins catalyze the
formation of diacylglycerol (DAG) from phosphatidic acid (PA) in
the penultimate step in triglyceride (TAG) synthesis. Recently, several
lines of evidences indicate that lipin-1 also acts as a transcriptional
regulator in the nucleus as well. Lipin-1 contains a putative nuclear
localization signal (NLS) and the lipin-1a isoform is localized in the
nucleus of liver cells [25] and mature adipocytes [14]. In yeast, the
homolog of lipin (Pah1p/Smp2p) associates with the promoter region
of genes involved in phospholipid biosynthesis and regulates the
expression of these genes [26]. In mammalian cells, lipin-1 can
interact with nuclear receptors such as PPARa,P P A R c, hepatocyte
n u c l e a rf a c t o r4 a, and glucocorticoid receptor [15]. Furthermore,
lipin-1 promotes PPARa-dependent gene expression in mouse liver
by mediating recruitment of PGC-1a and p300 [15]. Recently, it has
been suggested that lipin-1 also may function as a transcriptional
coactivator during adipogenesis [27] and exercise-induced mitochon-
drialbiogenesis[28].Uptonow,itremainstobedeterminedwhether
lipin-1 functions in the nucleus in neuronal cells.
In this study, we show that ectopically expressed lipin-1a is
localized in both the cytoplasm and the nucleus in neuronal cells,
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occurring at two consensus sites. We are able to detect
transcriptional coactivator effects of ectopic lipin-1a in neuronal
cells, and show that sumoylation is required for this activity,
consistent with the effects of sumoylation on the nuclear
localization of lipin-1a. Since we find that lipin-1 is expressed
and sumoylated endogenously in mouse brain, our work on
cultured neuronal cells raises the possibility that lipin-1 has
transcriptional functions in the brain that are controlled by
sumoylation.
Results
To determine whether the mammalian lipins are potential
targets for sumoylation, we examined the amino acid sequence of
lipin-1 (including lipin-1a and lipin-1b), lipin-2 and lipin-3. This
analysis revealed that both lipin-1a and lipin-1b contains two
sumoylation consensus motifs, and lipin-2 contains one (Figs. 1A
and 1B). We first evaluated whether lipin-1b, the longer isoform of
lipin-1, can be sumoylated in vitro. Immunopurified V5-tagged
lipin-1b was incubated with the SUMO E1 activating enzyme
Aos1/Uba2, the E2 conjugating enzyme Ubc9, and either
SUMO-1, SUMO-2 or SUMO-3, in the presence or absence of
ATP. Subsequent analysis of this reaction by immunoblotting with
anti-V5 antibody revealed the generation of two bands that
migrated more slowly than lipin-1b in the samples that contained
each of the three SUMO paralogs. The bands were strongest in
the sample incubated with SUMO-1, as compared to SUMO-2 or
SUMO-3 (Fig. 2A). The sizes of these products suggested that they
represented forms of lipin-1b that are modified with one or two
SUMO proteins (Fig. 2A). When ATP was absent from the
reaction, these bands were not detected (Fig. 2A), consistent with
the requirement of energy for SUMO conjugation [2]. These
results indicate that lipin-1b can be modified by SUMO-1,
SUMO-2, and SUMO-3 in vitro.
To examine whether lipin-1b can be sumoylated in vivo, HeLa cells
were co-transfected with plasmids encoding V5-tagged lipin-1b and
CFP-fused SUMO-1. Immunoblot analysis of extracts from these cells
with an anti-V5 antibody revealed a strong band corresponding to V5-
lipin-1baswell as aweaker, more slowlymigrating band atthe mobility
expected for V5-lipin-1b modified with one molecule of CFP-SUMO-
1 (Fig. 2B, lower arrowhead). A form of lipin-1bthat might be modified
with two molecules of CFP-SUMO-1 also was faintly detected (Fig. 2B,
upper arrowhead). To investigate whether these bands represent V5-
lipin-1b covalently conjugated to CFP-SUMO-1, a CFP-SUMO-1
mutant (G97A) that cannot be conjugated to target proteins [29] was
used instead of the wild-type CFP-SUMO-1. In this case, both
additional bands were absent (Fig. 2B). As a separate approach to
confirm that lipin-1b is modified by CFP-SUMO-1 in HeLa cells, a
lysate from the transfected cells was immunoprecipitated with an anti-
V5 antibody, and the immunoprecipitate was examined by immuno-
blotting with an anti-GFP antibody. This analysis revealed an anti-
Figure 1. Sequence organization and sumoylation motifs in lipins. (A) A schematic depicting the homologous regions in lipin-1a, lipin-1b,
lipin-2 and lipin-3, and the WKXE sumoylation motifs in lipin-1a, lipin-1b, and lipin-2. The N-terminal lipin-homology domain (NLIP) (blue), C-terminal
lipin-homology domain (CLIP) (green), and the predicted nuclear localization signal (NLS) (red) are indicated. Shown also is the relative location of the
lipin-1b-specific insert (purple). (B) Conservation of the WKXE sumoylation motifs of lipin-1 from various species.
doi:10.1371/journal.pone.0007031.g001
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form of V5-lipin-1b presumptively modified with one molecule of
SUMO-1 (Fig. 2C). Together, these experiments indicate that lipin-1b
is sumoylated in HeLa cells in vivo.
We next examined whether K599 or K629 of lipin-1b, each of
which are located within the sumoylation consensus sequence
WKXE, are the sites of sumoylation. As shown in Fig. 2B,
mutation of either K599 or K629 alone substantially reduced
sumoylation of lipin-1b. However, simultaneous mutation of the
two lysines completely abrogated the sumoylation of lipin-1b in
vivo. Furthermore, we found that the immunopurified V5-lipin-1b
mutant (K599/626R, ‘‘2KR’’) was not modified by SUMO-1 in
an in vitro sumoylation reaction (data not shown). This indicates
that lipin-1b can be sumoylated at either of the sumoylation
consensus sites. Although a form of lipin-1b that was modified with
two molecules of CFP-SUMO-1 was clearly seen by in vitro
sumoylation of lipin-1b using untagged SUMO-1 (Fig. 2A), this
form was scarcely detectable in the HeLa cell assay (Fig. 2B). This
discrepancy might be a consequence of steric interference by CFP
in the latter case, which could diminish modification of the second
lysine when the first lysine is sumoylated.
Next, we examined whether lipin-1a, the shorter splice isoform
of lipin-1 that lacks a 33 amino acid adjacent to the nuclear
localization sequence (NLS) (Fig. 1A), can be sumoylated in vivo.A s
shown in Fig. 3A, a band corresponding to lipin-1a modified with
one molecule of SUMO-1 was obtained when HeLa cells were
transfected with expression plasmids for V5-lipin-1a and CFP-
SUMO-1. A presumptive minor form of V5-lipin-1a with two
molecules of CFP-SUMO-1 is seen upon long exposure (Fig. S1).
The bands were not obtained when the mutant CFP-SUMO1-
G97A was used (Figs. 3A and S1). Furthermore, simultaneous
mutation of the two putative sumoylation sites (K566/596R,
‘‘2KR’’) also blocked lipin-1a sumoylation, similar to lipin-1b
(Fig. 3B and Fig. S1). However, both the G84R and D679E
mutations in lipin-1a that are linked to lipodystrophy [18] and
deficiency in PAP activity [15,30], respectively, did not lead to a
diminished sumoylation of lipin-1a (Fig. S1). In contract to the
results obtained with lipin-1, we did not detect sumoylation of
lipin-2 and lipin-3 in transfected HeLa cells (Fig. 3A), even though
lipin-2 bears a sumoylation consensus site (Fig. 1A). It is
conceivable that the potential sumoylation site of lipin-2 is
inaccessible in its 3-D structure and is never modified, or that
sumoylation of lipin-2 occurs only in a specific cellular context.
To investigate whether endogenous lipin-1 is sumoylated, we
examined mouse liver, muscle and brain, three of the tissues where
lipin-1 mRNA is expressed [31]. The tissues were lysed in the
absence or presence of N-ethylmaleimide (NEM), which inhibits
SUMO-specific proteases, and then were immunoprecipitated
with an anti-lipin-1 or anti-SUMO-1 antibody. Immunoblot
analysis of samples immunoprecipitated with anti-lipin-1 showed
that lipin-1 protein was present in all three tissues, albeit at much
higher levels in muscle than in the other two tissues (Fig. 4A). Our
results on the tissue expression of lipin-1 protein are consistent
with the relative mRNA levels reported for lipin-1 in these tissues
[31]. The multiple bands appearing in the liver sample
presumably result from specific post-translational modifications
of lipin-1 occurring in this tissue (e.g. phosphorylation [30,32])
(Fig. 4A). Immunoprecipitation with anti-SUMO-1 followed by
immunoblotting with anti-lipin-1 revealed a prominent sumoy-
lated form of lipin-1 in brain, but only when the tissue extracts
were prepared in the presence of NEM (Fig. 4B). Sumoylated
forms of lipin-1 in muscle and liver were only marginally detected
(Fig. 4B). These results suggest that sumoylation of lipin-1 may be
particularly important for its functions in brain. Thus, we focused
our subsequent analysis on neuronal cells.
Because sumoylation is known to regulate the nuclear
localization of some of its target proteins, we examined whether
sumoylation of lipin-1 affects its subcellular distribution in primary
neurons. Cerebrocortical neurons from embryonic day 17 rat
embryos were isolated and cultured for 3 days in vitro. Cells then
were transfected either with V5-tagged lipin-1a or lipin-1b,o r
Figure 2. Lipin-1b is sumoylated at two consensus sumoylation
sites. (A) Immunopurified V5-tagged lipin1b was incubated with or
without recombinant SUMO-1, 2, or 3, the E1 enzyme Aos1/Uba2 and
the E2-conjugating enzyme Ubc9 as indicated. The reaction mixture
then was analyzed by immunoblotting with anti-V5 antibody. Asterisks
indicate forms of lipin1b (arrowhead) that are modified with one or two
SUMO molecules. (B) HeLa cells were cotransfected with V5-lipin-1b
together with CFP-SUMO-1 or CFP-SUMO-1-G97A as indicated. 48 h
after transfection, the cells were directly lysed in Laemmli sample buffer
supplemented with 10 mM NEM and analyzed by immunoblotting (IB)
with anti-V5 (upper panel) or anti-GFP (lower panel) antibody. In the
upper panel, the arrowheads indicate the slower migrating forms of
lipin-1b. In the lower panel, the free CFP-SUMO1 and the endogenous
proteins conjugated with CFP-SUMO-1, respectively, are indicated. (C)
Lysates of HeLa cells expressing V5-tagged lipin-1b and CFP-tagged
SUMO-1 were subjected to immunoprecipitation (IP) with anti-V5
antibody, followed by immunoblotting (IB) with anti-GFP to detect
sumoylated lipin-1b. Asterisks denote the sumoylated form of lipin-1b.
doi:10.1371/journal.pone.0007031.g002
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days later the subcellular distribution of the lipin-1 isoforms were
detected by immunofluorescence with anti-V5 antibody. As shown
in Fig. 5, ectopic lipin-1a exhibited both nuclear and cytoplasmic
localization in embryonic cortical neurons, with a higher
concentration in the nucleus. In contrast, lipin-1b showed
exclusively cytoplasmic localization and was excluded from the
nucleus. Interestingly, the sumoylation site lipin-1a-2KR mutant
almost completely lost its nuclear localization compared to wild-
type lipin-1a, although its cytoplasmic localization remained
unchanged. Also, the almost exclusively cytoplasmic localization
of lipin-1b did not change with its sumoylation site mutant (Fig. 5).
To extend the observations obtained with cortical neurons, we
generated SH-SY5Y neuronal cell lines stably expressing V5-lipin-
1a or V5-lipin-1a-2KR. Two clones were examined for each
transfectant to control for potential non-specific effects of stable
chromosomal integration. Immunoblot analysis revealed that the
V5-lipin-1a and V5-lipin-1a-2KR were expressed at comparable
levels in these clones (Fig. 6A). Employing immunofluorescence
analysis of these SH-SY5Y clones, we observed that ectopic lipin-
1a exhibited both nuclear and cytosolic localization, with a higher
concentration in the nucleus (Fig. 6B). Conversely, lipin-1a-2KR
showed almost exclusively cytoplasmic localization (Fig. 6B),
similar to our findings in cortical neurons (Fig. 5). Identical results
were obtained with both of the V5-lipin-1a and V5-lipin-1a-2KR
stable clones (data not shown). We confirmed that in both cortical
neurons and SH-SY5Y cells, the lipin-1a was sumoylated at the
two consensus sites (Fig. S2). Interestingly, the sumoylation-
dependent nuclear localization of lipin-1a appears to occur in a
cell type-specific manner. Whereas sumoylation facilitated nuclear
distribution of lipin-1a in HeLa cells, as judged by the analysis of
lipin-1a and the lipin-1a-2KR mutants, both of these forms of
lipin-1a were concentrated in the cytoplasm in HEK293A (Fig.
S3), thus suggesting a cell-type-specific cytosolic/nuclear retention
mechanism.
The presence of lipin-1a in both the nucleus and the cytoplasm
of neuronal cells suggests that it may be a nucleocytoplasmic
shuttling protein. Since nuclear accumulation is required for a
nucleocytosolic shuttling protein to function in regulation of gene
expression, we examined whether sumoylation can regulate the
activity of lipin-1a as a transcriptional coactivator. We first
examined effects on lipin-1a stimulation of PGC-1a activity,
which was originally described in liver [15]. For this purpose, SH-
SY5Y neuronal cells that stably overexpressed lipin-1a or lipin-1a-
2KR were transfected with a vector encoding a GAL4-PGC-1a
Figure 3. Lipin-1a, but not lipin-2 and lipin-3 is sumoylated in HeLa cells. (A and B) HeLa cells were cotransfected with CFP-SUMO-1 or CFP-
SUMO-1-G97A together with V5-lipin-1a, V5-lipin-2 or V5-lipin-3 (A) or with V5-lipin-1a-2KR (B) as indicated. 48 h after transfection, the cells were
directly lysed in Laemmli sample buffer supplemented with 10 mM NEM and analyzed by immunoblotting with anti-V5 (upper panel) or anti-GFP
(lower panel) antibody. In the upper panels, the arrowheads indicate the slower migrating form of lipin. In the lower panel, the free CFP-SUMO1 and
the endogenous proteins conjugated with CFP-SUMO-1, respectively, are indicated. The levels of CFP-SUMO-conjugates varied due to different
exposures.
doi:10.1371/journal.pone.0007031.g003
Figure 4. Sumoylation of lipin-1 in mouse tissues. Tissue samples
were prepared in lysis buffer with or without NEM. After determination
of protein concentrations, 1 mg of tissue extracts were immunopre-
cipitated with anti-lipin-1 (A) or anti-SUMO-1 (B). The immunoprecip-
itates were analyzed by immunoblotting with anti-lipin-1 antibody.
doi:10.1371/journal.pone.0007031.g004
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plasmid. As shown in Fig. 7A, the transactivation mediated by the
PGC-1a fusion protein was significantly enhanced in cells
expressing lipin-1a, but not in cells expressing lipin-1a-2KR.
Thus, lipin-1a can stimulate the transcriptional coactivation
function of PGC-1a in cultured neuronal cells in a sumoylation-
dependent manner.
We next examined a possible effect of lipin-1a and its
sumoyation on the transcriptional activity of MEF2, a transcrip-
tion factor that regulates neuronal survival and differentiation [33-
36]. We found that SH-SY5Y cells overexpressing lipin-1a showed
marked stimulation of the transcriptional activity of endogenous
MEF2, using an MEF2-responsive luciferase plasmid as a reporter
(Fig. 7B). We also observed that overexpressed lipin-1a stimulated
the transactivation of two separate MEF2 isoforms (MEF2A and
MEF2D), using a Gal4-MEF2 fusion transactivation system
(Figs. 7C and D). The possibility that lipin-1a stimulates the
transcriptional activity of MEF2 by a direct coactivator mecha-
nism is supported by our finding that lipin-1a coimmunoprecipi-
tated with endogenous MEF2C in mouse brain extract (Fig. S4A)
and with ectopically expressed MEF2C in HEK293A cells (Fig.
S4B). As predicted, the lipin-1a mutant that was deficient in
nuclear localization also showed a defect in stimulation of MEF2
transcription (Figs. 7B-7D). Thus, these data suggest that
sumoylated lipin-1a is a transcriptional coactivator for MEF2 as
well as for PGC-1a, as demonstrated previously.
The defect of lipin-1a-2KR in transcriptional coactivation
apparently was not due to a loss of PAP1 activity, as
immunopurified lipin1a-2KR obtained from SH-SY5Y cells still
retained Mg
2+-dependent phosphatase activity for PA (C8), but
not for LPA (C18:1), determined with the malachite green assay
(Fig. S5). In contrast, immunopurified V5-LPP3 (a PAP2 family
member) was able to dephosphorylate both PA (C8) and LPA
(C18:1) in a Mg
2+-independent manner (data not shown). Lipin-
Figure 5. Localization of lipin-1 isoforms and sumoylation site mutants in rat embryonic cortical neurons. Cortical neurons were
cotransfected with GFP and the indicated plasmids. 48 h later, the localization of the V5-tagged proteins (red) was determined by
immunofluorescence with anti-V5 antibody. Nuclei (blue) were visualized with Hoechst 33342 staining. GFP fluorescence (green) was also captured.
The magnified images for V5-lipin-1 immunostaning were also provided to more clearly show the cytosolic distribution of lipin-1a,1 b, and their
mutants. Bar, 10 mm.
doi:10.1371/journal.pone.0007031.g005
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and MEF2C, as determined by coimmunoprecipitation from co-
transfected HEK293A cells (Figs. S4B and S4C), where both lipin-
1a and lipin-1a-2KR were cytoplasmically localized (Fig. S3).
Together, these observations suggest that sumoylation regulates
the nuclear localization and the coactivator activity of lipin-1a in
neuronal cells.
Discussion
Lipin-1 has important functions as both a PAP and a
transcriptional coactivator, but relatively little is known about
post-translational regulation of its functions. The only previously
characterized posttranslational modification of lipin-1 is phos-
phorylation, which can regulate its localization to the ER
membrane vs cytosol [30], and its PAP activity during the cell
cycle [32]. Also, the transcriptional coactivator function of the
yeast homolog of lipin-1, Pah1p, is regulated by the phosphatase
Nem1p [26]. However, it remains unknown how the mammalian
homolog of yeast Nem1p, the nuclear envelope protein Dullard/
NET56 [37,38] might affect nuclear functions of mammalian
lipin-1.
Our current study reveals for the first time that lipin-1a and
lipin-1b undergo sumoylation in vivo. Although most of our work
involved analysis of lipin-1 that was ectopically expressed in
cultured cells, we also demonstrated that endogenous lipin-1 in
Figure 6. Localization of lipin-1a and lipin-1a-2KR in stably transfected SH-SY5Y cells. (A) Immunoblot analysis of V5-lipin-1a and V5-lipin-
1a-2KR in stably transfected SH-SY5Y cell clones. Shown is analysis of two separate V5-lipin-1a clones (wt-1 and wt-2), and two separate V5-lipin-1a-
2KR clones (2KR-1 and 2KR-2). (B) SH-SY5Y cells stably transfected with V5-lipin-1a (wt-1) or V5-lipin-1a-2KR (2KR-1) were subjected to
immunostaining with anti-V5 antibody (green). F-actin (red) and nucleus (blue) were stained with Alex598-Phalloidin and Hoechst 33342, respectively.
Bar, 10 mm.
doi:10.1371/journal.pone.0007031.g006
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lipin-1 is physiologically relevant. In the cultured cell models we
examined, lipin-1 sumoylation occurs on the two consensus
sumoylation sites present in both lipin-1a and lipin-1b. We found
that lipin-1a, which is the predominant lipin-1 isoform in the brain
[14], is concentrated in the nucleus in both embryonic cortical
neurons and cultured SH-SY5Y neuronal cells, and that its
nuclear localization is dependent on the presence of functional
sumoylation sites. In contrast, lipin-1b is mostly excluded from the
nucleus in the neuronal cells we examined.
Our observations on the different nucleocytoplasmic localizations of
lipin-1a and lipin-1b in neuronal cells are reminiscent of previous
findings in mature adipocytes, where lipin-1a and lipin-1b were found
to be localized to the nucleus and to the cytoplasm, respectively [14].
Although we do not yet know how sumoylation facilitates the nuclear
localization of lipin-1a in neuronal cells, sumoylation might influence
its nuclear localization by controlling interactions with the nuclear
import/export machinery, and/or by regulating its binding to
intranuclear components. In this regard, a recent survey of proteins
whose nuclear localization is facilitated by sumoylation reveals that
sumoylation sites are frequently located in close proximity to NESs
[13]. In these cases, sumoylation might affect nuclear export by
inhibiting the binding of NESs to export receptors. The relevance of
this mechanism to nuclear export of lipin-1aremains to be determined.
Sumoylation of lipin-1a, in addition to mediating its nuclear
localization, also appears to be required for its transcriptional
coactivator activity toward PGC-1a and MEF2 in neuronal cells
(see paragraph below). This transcription-related effect of
sumoylation most likely is a simple consequence of its ability to
mediate the nuclear localization of lipin-1a, since the sumoylation
site mutant of lipin-1a still retains the ability to associate with
PGC-1a and MEF2 in cultured cells. We also determined that
sumoylation does not influence the PAP1 activity of lipin-1a. This
is consistent with the notion that the lipin homologs in yeast and in
invertebrates bears no consensus sumoylation site, even though
lipin has PAP1 activity in all eukaryotes examined.
Although lipin-1 is known to be involved in regulation of gene
expression in liver and adipocytes, its functional relevance to gene
Figure 7. Effect of lipin-1a and lipin-1a-2KR on coactivation of PGC-1a and MEF2 in SH-SY5Y cells. SH-SY5Y clones stably expressing V5-
lipin-1a or V5-lipin-1a-2KR were transfected with Gal4-PGC-1a and (UAS)5-TATA-Luc (A), MRE-Luc (B), Gal4-MEF2A and (UAS)5-TATA-Luc (C), or Gal4-
MEF2C and (UAS)5-TATA-Luc (D). 36 h later, the relative luciferase activity was determined. Error bars indicate standard deviations from 4
independent samples.
doi:10.1371/journal.pone.0007031.g007
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lipin-1a shows both nuclear localization and transcriptional
coactivator activity towards PGC-1a in neuronal cells, suggest
that it indeed may act as a transcriptional coactivator in brain.
Furthermore, our results argue that sumoylation of lipin-1a is
likely to be important for these putative brain functions. PGC-1a
was recently found to have major functions in brain, since it
controls the expression of a subgroup of antioxidant genes [39],
and its dysfunction is associated with neurodegenerative diseases
[40–42]. Our findings, therefore, may provide new clue to
understand the regulation of PGC-1a in brain.
Whereastheabilityoflipin-1topromotethecoactivationofgenes
by PGC-1a has been previously established [15], our results for the
first time indicate that lipin-1a also can associate with and
coactivate MEF2, a critical transcription factor in control of neuron
survival and differentiation [35,36]. However, it remains to be
determined whether this coactivation occurs at the level of MEF2-
associated promoters, and which of the MEF2-target genes are
regulated by lipin-1a. It should be pointed out that PGC-1a can
stimulate its own promoter by coactivating MEF2 [43]. Moreover,
PGC-1a can positively regulate lipin-1 expression [15]. In this
regard, lipin-1a mayserveas anamplifierof PGC-1a-MEF2 loop in
neuronal cells, using sumoylation as a molecular switch.
In summary, we have shown that sumoylation can serve as a
molecular switch to control the nuclear localization and
coactivator activity of lipin-1a in cultured neuronal cells. Our
results raise the possibility that lipin-1a acts as a sumoylation-
regulated transcriptional coactivator in brain; however, the effects
of lipin-1b sumoylation remain to be determined. Identifying the
functions of lipin-1 sumoylation in brain (e.g. which genes are
transcriptionally controlled by this mechanism and whether this is
linked to neuron survival or differentiation) and revealing its
physiological and pathological relevance (e.g. whether this is
involved in regulation of learning and memory and/or implicated
in neuropathy) represent important challenges in future studies.
Materials and Methods
Chemicals, plasmids and antibodies
Phosphatidic acid (PA: C8), and lysophosphatidic acid (LPA:
C18:1) were purchased from Avanti Polar Lipids. N-ethylmalei-
mide (NEM) was purchased from Sigma. V5-tagged lipin-1a,
lipin-1b, lipin-2 and lipin-3 expression vectors were kind gifts from
Dr. Karen Reue (University of California, Los Angeles) [14,31];
CFP-SUMO-1 and CFP-SUMO-1(G97A) were generously pro-
vided by Dr. Takashi Osumi (University of Hyogo, Japan) [29];
Gal4-MEF2A and Gal4-MEF2C were kindly provided by Hung-
Ying Kao (Case Western Reserve University and the Research
Institute of University Hospitals of Cleveland) [44]; Gal4-PGC-1a
and Myc-PGC-1a were gifts from Daniel Kelly (Washington
University School of Medicine) [15]; (UAS)5-TATA-Luc was
described previously [45,46]. All the plasmid-based mutations
employed in this study were created using GeneTailor
TM site-
directed mutagenesis system (Invitrogen) according to the
manufacturer’s protocol. The rabbit anti-mouse lipin-1 antibody
was kindly provided by Thurl E. Harris (University of Virginia)
[22,30]. The following antibodies were obtained commercially:
anti-V5 (Invitrogen); anti-Myc (Santa Cruz Biotechnology, Inc);
anti-lipin-1 (Chemicon); anti-alpha-tubulin (Abcam); anti-MEF2C
(Santa Cruz Biotechnology, Inc); anti-GFP (Santa Cruz Biotech-
nology, Inc); anti-Gal4 (Santa Cruz Biotechnology, Inc); anti-V5
agarose (Sigma); anti-SUMO1 agarose (Santa Cruz Biotechnolo-
gy, Inc); Alexa Fluor488
TM or Alexa Fluor568
TM anti-IgG
antibody (Invitrogen); HRP-conjugated anti-IgG antibody (Pierce).
Cell culture and transfection
HeLa and SH-SY5Y cells were purchased from ATCC,
HEK293A cells were purchased from Invitrogen. They were all
maintained in DMEM supplemented with 10% fetal bovine serum
(FBS) (Invitrogen) and antibiotics. Rat cortical neuron cultures
were prepared as described previously [47]. Cell transfections were
performed with Lipofectamine
TM 2000 (Invitrogen). Stable SH-
SY5Y populations were generated by selection with 400 mg/ml
G418 for 3 weeks and 2 independent clones were chosen. The
clones were confirmed by immunostaining with anti-V5 antibody,
which revealed that 100% of the cells were positive for V5-lipin-1a
or V5-lipin-1a-2KR.
Immunoprecipitation and immunoblotting
Cells were harvested 48 h after transfection and lysed by brief
sonication in lysis buffer (50 mM Tris pH 7.5, 250 mM NaCl,
1 mM EDTA, 1 mM EGTA, 0.5% Triton X-100, 10% glycerol,
complete Protease Inhibitor Cocktail (Roche Diagnostics)). Lysates
were subjected to immunoprecipitation with anti-V5 agarose.
Immune complexes were washed five times with lysis buffer and
subjected to immunoblotting with anti-GFP, anti-Gal4, or anti-
Myc antibody.
In vitro and in vivo sumoylation
For in vitro sumoylation experiments, HEK293A cells were
transfected with plasmids expressing V5-tagged proteins. 48 h
later, lysates were subjected to immunoprecipitation with anti-V5
agarose, and immune complexes were eluted with V5-peptide
(100 mg/ml). The immunopurified proteins were incubated with
2 mg of recombinant SUMO-1 (BIOMOL), 0.5 mg of Aos1/Uba2
(BIOMOL International), and 0.1 mg of Ubc9 (BIOMOL) for 2 h
in 20 ml of 50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 2 mM ATP.
The reaction mixture was analyzed by immunoblotting with anti-
V5 antibody. In vivo sumoylation analysis was performed as
previously described [48]. In brief, HeLa cells were transfected
with expression plasmids for V5-lipin-1b and CFP-SUMO-1 (or
their mutants). 48 h after transfection, cells were directly lysed in
Laemmli SDS gel buffer supplemented with 10 mM NEM.
Extracts were boiled for 10 min prior to loading on SDS-
polyacrylamide gels. To detect sumoylation of endogenous lipin-1,
tissue samples were cut into small pieces in ice-cold PBS
containing 10 mM NEM, lysed by douncing and subsequent
sonication in ice-cold lysis buffer (50 mM Tris pH 7.5, 250 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM NEM, 0.5% Triton
X-100, 10% glycerol, complete Protease Inhibitor Cocktail (Roche
Diagnostics)). The lysates were incubated with anti-SUMO-1
agarose or lipin-1 antibody followed by protein A/G PLUS (Santa
Cruz Biotechnology, Inc) with agitation overnight. Immune
complexes were analyzed by immunoblotting with anti-lipin-1
antibody.
Immunofluorescence microscopy
Immunofluorescent staining was performed as previously
described [49]. In brief, cells were fixed with 4% formaldehyde
in PBS for 30 min. Following fixation, cells were treated with 0.2%
Triton X-100 in PBS for 5 min. After blocking with 10% FBS in
PBS for 20 min, cells were incubated for 1 h with primary
antibody, followed by washing in PBS and incubation for 1 h with
the relevant secondary antibody. F-actin and nuclei were stained
with Alex598-Phalloidin and Hoechst 33342 (Invitrogen), respec-
tively. The stained cells on cover slips were subsequently mounted
in Gel Mount
TM (Biomeda) and sealed with Clarion
TM (Biomeda).
Cell images were taken with the BioRad-Zeiss Radiance 2100
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2000
TM software (Bio-Rad). Images were pseudo-colorized and
merged with ImageJ.
Lucifease assay
The luciferase assay was performed as previously described
[45,46].
PAP1 activity assay
SH-SY5Y cells stably expressing pcDNA3, lipin-1a-V5 or lipin-
1a-2KR-V5 were lysed by scraping into ice cold lysis buffer
(50 mM Tris pH 7.5, 250 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 0.5% Triton X-100, 10% glycerol, complete Protease
Inhibitor Cocktail (Roche Diagnostics)). Samples were sonicated
on ice and centrifuged at 16,000 g at 4uC for 30 min. The
supernatant was mixed with anti-V5 agarose and rotated at 4uC
overnight. The beads were washed with lysis buffer 4 times, and
with the assay buffer (100 mM Tris-maleate, pH 6.5, 0.5% Triton
X-100, 10 mM DTT) twice. The recombinant lipin-1a-V5 or
lipin-1a-2KR-V5 was eluted by the incubation with 70 ml V5-
peptide (100 mg/ml) in assay buffer for 1 h at 4uC with agitation.
After brief centrifugation, the supernatants were subjected to
either immunoblotting with anti-V5 antibody or analysis of PAP1
activity using the malachite green colorimetric assay as described
previously [50,51], with minor modifications. In brief, the assays
were performed in 96-well, clear, non-binding surface assay plates
(Corning Incorporated) in 40 ml of assay buffer containing either
PA or LPA at 100 mM in the absence or the presence of 5 mM
MgCl2 and 10 ml of immuno-purified lipin-1a-V5 or lipin-1a-
2KR-V5. The reaction was carried out at 37uC for 90 min and
stopped with 100 ml of malachite green reagent (BIOMOL), and
the absorbance was read at 650 nm according to the manufac-
turer’s instructions. The enzyme reactions were linear over time
and protein concentration.
Supporting Information
Figure S1 Sumoylation of various lipin-1a mutants in HeLa
cells. Cells were cotransfected with V5-lipin-1a or the indicated
lipin1 mutants, together with CFP-SUMO-1 or CFP-SUMO-1-
G97A, as indicated. 48 h after transfection, the cell lysates were
lysed in Laemmli sample buffer supplemented with 10 mM NEM
and analyzed by immunoblotting (IB) with anti-V5 (upper panel)
or anti-GFP (lower panel) antibody. In the upper panels, the
arrowheads indicate the slower migrating forms of lipin-1a. In the
lower panel, the free CFP-SUMO1 and the endogenous proteins
conjugated with CFP-SUMO-1, respectively, are indicated.
Found at: doi:10.1371/journal.pone.0007031.s001 (0.43 MB TIF)
Figure S2 Sumoylation of lipin-1a and lipin-1a-2KR in
neuronal cells. SH-SY5Y cells (A) or cortical neurons (B) were
cotransfected with V5-lipin-1a or V5-lipin-1a-2KR, together with
CFP-SUMO-1 or CFP-SUMO-1-G97A as indicated. 48 h after
transfection, the cells were directly lysed in Laemmli sample buffer
supplemented with 10 mM NEM and analyzed by immunoblot-
ting with anti-V5 antibody. The arrowheads indicate the slower
migrating form of lipin-1a.
Found at: doi:10.1371/journal.pone.0007031.s002 (0.12 MB TIF)
Figure S3 Localization of lipin-1a and lipin-1a-2KR in
HEK293A and HeLa cells. HEK293A cells (A) or HeLa cells (B)
were transfected with lipin-1a and lipin-1a-2KR. 48 h later, the
cells were subjected to immunostaining with anti-V5 antibody
(green). F-actin (red) and nucleus (blue) were stained with Alex598-
Phalloidin and Hoechst 33342, respectively. Bar, 10 mm. (C) The
distribution patterns of V5-lipin-1a, V5-lipin-1b, or their mutants
were scored for almost 100 cells and classified into three
categories: C.N, cytoplasmic-dominant distribution; N=C,
roughly equal distribution in nuclear and cytoplasmic compart-
ments; and C,N, nuclear-dominant distribution.
Found at: doi:10.1371/journal.pone.0007031.s003 (1.03 MB TIF)
Figure S4 Sumoylation site lipin-1a mutant retains the capacity
to associate with MEF2C and PGC-1a. (A) Mouse brain extract
was prepared and immunoprecipitated with anti-lipin-1 antibody
or a control IgG, and the MEF2C present in the immunoprecip-
itates was analyzed by immnoblotting. (B, C) HEK293A cells were
transfected with V5-lipin-1a or V5-lipin-1a-2KR, together with
Gal4-MEF2C (B) or Myc-PGC-1a (C). 48 h later, the cell lysates
were subjected to immunoprecipitation with anti-V5 agarose, and
the presence of Gal4-MEF2C (B) or Myc-PGC-1a (C) in the
immunoprecipitates was analyzed by immunoblotting with anti-
Gal4 or anti-Myc antibody.
Found at: doi:10.1371/journal.pone.0007031.s004 (0.33 MB TIF)
Figure S5 Lipin-1a and lipin-1a-2KR have comparable PAP1
activity in stably transfected SH-SY5Y cells. (A) V5-tagged lipin-
1a or lipin-1a-2KR was immunopurified from SH-SY5Y cells and
then subjected to the PAP1 activity analysis using PA as the
substrate. Bottom: The expression of immunopurified lipin-1a or
lipin-1a-2KR was determined by immunoblotting with anti-V5
antibody. (B) Immunopurified lipin-1a was subjected to the PAP1
activity analysis using PA or LPA as the substrate, in the presence
or absence of Mg
2+.
Found at: doi:10.1371/journal.pone.0007031.s005 (0.12 MB TIF)
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